Claude Drug Discovery Trials Cut Batch Record Review Time by 89%
Anthropic reports early Claude results with six drug developers. At Enveda it cut batch-record review time 89% and caught seven issues humans missed.
Artificial intelligence is reshaping how discovery happens across chemistry, biology, physics, and energy research. Rather than replacing scientists, machine learning models are becoming powerful collaborators—sifting through molecular libraries, predicting protein structures, simulating physical systems, and identifying patterns in datasets too large or complex for traditional analysis. This shift is compressing timelines that once spanned years into months or weeks, particularly in fields like drug discovery, materials science, and clean energy research.
Why now? Three forces are converging: dramatic improvements in generative and predictive AI models, the availability of specialized computing hardware built for scientific workloads, and growing pressure from industry and governments to accelerate breakthroughs in medicine, energy security, and advanced computing. Pharmaceutical companies are racing to embed AI systems directly into drug discovery pipelines, while national labs and tech firms are exploring how quantum computing and machine learning together might unlock advances in areas like fusion energy. At the same time, the computational demands of these AI systems are prompting a closer look at energy consumption—creating both challenges and unexpected opportunities for clean power innovation.
Readers of this hub will find ongoing coverage of how major pharmaceutical and technology companies are deploying AI platforms for drug and materials discovery, how quantum computing is being paired with machine learning to tackle previously intractable scientific problems, and how the energy costs of AI infrastructure are influencing the broader clean energy landscape. Expect reporting on new partnerships, deployed systems, research breakthroughs, and the infrastructure debates shaping the future of scientific discovery—tracking both the promise and the practical trade-offs of AI-accelerated science.
Anthropic reports early Claude results with six drug developers. At Enveda it cut batch-record review time 89% and caught seven issues humans missed.
Anthropic bought Mithril Medicine, AstraZeneca signed an AI deal with insitro worth up to $1.86B, and AI protein design funding passed $1B in 2026.
Insilico Medicine dosed the first patient in a 320-person Phase III trial of rentosertib, an IPF drug whose target and molecule were both found by AI.
Insilico's rentosertib entered Phase 3 in September 2026. AI protein design hit rates are rising, while Isomorphic Labs still hasn't started human trials.
AstraZeneca will pay insitro $40M upfront, plus up to $1.46B in milestones, to use its Virtual Human AI platform to find MASH and cardiomyopathy drug targets.
Insilico's AI-designed rentosertib entered Phase III in July 2026, while Isomorphic Labs has yet to dose a patient and AI antibody design advances.
Baker lab's AI-designed proteases, Chai's GSK deal and Generate's $1.2B Zealand pact show AI protein design moving from structure prediction to drug deals.
AstraZeneca will pay insitro $40M upfront and up to $1.46B in milestones to use its Virtual Human AI platform to find MASH and cardiomyopathy drug targets.
AstraZeneca will pay insitro $40M upfront, plus up to $1.46B in milestones, to use AI to find drug targets for MASH and cardiomyopathies.
AstraZeneca will pay insitro $40M upfront to use its Virtual Human AI platform to find MASH and cardiomyopathy targets. Milestones could add about $1.46B.
DOE announced 12 Genesis Mission Phase II AI-for-science awards, including Commonwealth Fusion Systems, plus a 4-year PhD pilot, amid funding worries.
A new paper finds OpenAI's Lean-verified Navier-Stokes code diverges from its written proof in two places, as its 722-report math release faces scrutiny.
Absci shares and analyst targets are climbing even as AWS pushes into AI drug discovery via a Novo Nordisk hub, challenging the hyperscaler squeeze thesis.
Eli Lilly signed a deal worth up to $2.75B with Insilico Medicine, paying $115M upfront to license AI-discovered oral drugs, reportedly a GLP-1 candidate.
Chai Discovery raised $400M in a July Series C, with OpenAI among backers, valuing the AI antibody-design startup at $3.8B before a mature clinical pipeline.
OpenAI released 722 AI-generated math manuscripts covering about 372 result families. Fewer than half are machine-checked, and the results point to wider
Paris-based WhiteLab Genomics raised a $26M Series B led by AVP to expand animal testing of its AI-designed gene delivery vehicles and grow pharma partnerships.
OpenAI released 722 unreviewed AI-generated math manuscripts claiming a quasi-Riemann hypothesis proof with Lean verification, igniting fury and debate in the
China's EAST tokamak ran stable plasmas at 1.3 to 1.65 times the Greenwald density limit, the first confirmation of a predicted density-free regime.
ByteDance's Protenix-v1, Biohub's ESMFold2 and other new open protein structure models report AlphaFold 3-level accuracy and allow free commercial use.
DeepMind, NVIDIA, EMBL-EBI and partners released predicted protein-complex structures for 2,800+ viruses in the AlphaFold Database to aid pandemic readiness.
AI-designed drugs reach Phase 3 and protein-design startups raise billions, but validation gaps and Anthropic's disputed CRISPR claim temper the speed story.
France's WEST tokamak held a plasma for a record 1,337 seconds. The real value of the run is what it showed about tungsten walls and plasma control for ITER.
NVIDIA, Google DeepMind and EMBL-EBI released AI-predicted protein complex structures for 2,800+ viruses in the AlphaFold Database, plus an open BioNeMo
In September 2026, AbbVie signed AI deals with Iambic and Valkai and joined AISB Bind, a federated binding-prediction project, after pharma models beat public
China's ENN Group says its EXL-50U tokamak produced over 100 million hydrogen-boron fusion reactions per second, confirmed by repeatable alpha-particle data.
AstraZeneca pays insitro $40M upfront and up to ~$1.46B in milestones for AI target discovery as protein design funding and CRISPR clinical milestones pile up.
CRISPR is shifting to in-body editing: Intellia nears the first in vivo approval, UCSF builds CAR-T inside mice, and AI-designed editors beat natural enzymes.
Ozempic maker Novo Nordisk is partnering with Anthropic and OpenAI to compress drug discovery timelines and find its next blockbuster medicine.
Six AI aging clocks found lower biological age in IPF patients on AI-designed drug rentosertib, but effects in healthy people remain untested.